Artiva Cuts 94% of Staff, Kills AlloNK After Two Trial Deaths

Artiva Biotherapeutics will cut approximately 94% of its workforce — roughly 98 of the 104 full-time employees it reported as of June 30 — and has terminated development of its sole lead candidate after two patient deaths in a Phase IIa trial, one of them assessed as likely related to fludarabine toxicity. Shares fell 30.5% on Tuesday, from $6.16 to $4.27 by 2:04 p.m. ET, and at least five investment firms downgraded the stock.

The discontinued candidate, AlloNK (also AB-101), is a non-genetically modified, allogeneic (donor-derived), cryopreserved NK cell therapy (a treatment using natural killer cells, a component of the innate immune system). It was under evaluation in a Phase IIa basket trial (NCT06991114) in rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies, and systemic sclerosis, in combination with rituximab — the monoclonal antibody marketed as Rituxan by Roche's Genentech and Biogen.

What happened to the two patients?

The first patient died of leukoencephalopathy, a fatal neurological event, after treatment that included protocol-specified lymphodepletion (pre-conditioning chemotherapy) with cyclophosphamide and fludarabine. "The investigator and an independent safety review assessed the event as likely related to fludarabine-associated neurotoxicity," Artiva stated, adding that because fludarabine-containing lymphodepletion regimens are widely used in cell therapy development, it intends to publish additional case details in a scientific publication.

After Artiva reported the event to the FDA and the trial's data safety monitoring board (DSMB), the agency requested that the company pause enrollment and dosing in the Phase IIa study. Artiva also paused plans to begin enrollment and dosing in a planned Phase III trial of AlloNK.

The second patient experienced sudden death roughly two months after starting study treatment. "The investigator assessed this event as unrelated to AlloNK or any other component of the study treatment regimen, and the cause of death has not been determined," the company stated. This death was also reported to the FDA and the DSMB.

Why did Artiva end the program?

Beyond the fatalities, Artiva cited uneven clinical data and its assessment of the therapy's risk-benefit balance, the likelihood of future enrollment delays, and the overall development and potential commercial outlook. The data, according to the company, "continued to demonstrate deep B cell depletion and clinical activity consistent with the Company's previously reported findings." But longer-term follow-up "did not reflect the level of durability of clinical response the Company believes is needed to support continued development."

That durability gap — measurable short-term B cell depletion without sustained clinical response — is the specific efficacy failure that, combined with the safety events, closed the program. Artiva said it will work with the FDA, investigators, and institutional review boards on an orderly close-out, including continued safety monitoring and reporting.

CEO Fred Aslan, MD, said: "Throughout the development of AlloNK, the safety and well-being of patients have remained our highest priority. We are deeply saddened by the deaths of two patients who participated in our clinical studies and extend our sincere condolences to their families." He added that the company plans to publish findings from the first case, given fludarabine's widespread use in cell therapy conditioning regimens.

What does the strategic review cover?

Artiva has retained Leerink Partners to evaluate internal options and strategic alternatives intended to maximize stockholder value. Options under review include:

• a merger or business combination
• sale or licensing of assets
• dissolution and liquidation

The company said it does not plan to provide updates "unless and until the Board of Directors has approved a specific course of action, the process has concluded, or the Company determines that further disclosure is appropriate or required by law."

As of September 30, 2026, Artiva held approximately $319.1 million in cash, cash equivalents, and investments — a preliminary, unaudited figure. The announcement did not quantify expected costs of the workforce reduction. Complete quarterly results will appear in the Form 10-Q for the quarter ended September 30, 2026.

The company also canceled a planned AlloNK data presentation at ACR Convergence 2026 (November 6–11, Orlando, FL) and an investor webcast scheduled for November 9. "Updated clinical data may be presented at future scientific meetings depending on the outcome of the strategic alternatives process," Artiva said.

How did analysts respond?

Cantor Fitzgerald, TD Cowen, Needham & Co., H.C. Wainwright, and Wedbush all downgraded Artiva stock. At Wedbush, David Nierengarten, PhD, managing director and senior analyst covering small-mid cap biotech, cut his rating from "Outperform" to "Neutral" and reduced his 12-month price target by 90%, from $40 to $4.

Whether the $319 million cash position and the pending fludarabine case publication can attract a buyer or partner before the review concludes is now the central question for Artiva's remaining six employees and its shareholders.